Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Antithrombotic Trialists’ Collaboration

Many trials have been carried out with aspirin and other antiplatelet agents, demonstrating efficacy in the reduction of serious vascular events in a wide variety of patients at high risk of such events...

Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies
K. Wilson, N. Gibson, A. Willan, D. Cook

This paper comprises a meta-analysis of 12 articles addressing the risk after myocardial infarction, and the impact of smoking cessation...

Secondary prevention of coronary heart disease in the elderly
C. J. Bulpitt

Bulpitt, in this paper, discusses strategies for secondary prevention of established and stable coronary artery disease in the elderly and the very elderly (age 80 years or more)...

Beta blockade during and after myocardial infarction: an overview of the randomized trials
S. Yusuf, R. Peto, J. Lewis, R. Collins, P. Sleight

At the time this paper was published, 65 trials had enrolled 50 000 patients to determine the effects of ß-blockers in the treatment of myocardial infarction (MI)...

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais; the Heart Outcomes Prevention Evaluation Study Investigators

HOPE, (Heart Outcomes Prevention Evaluation) established evidence of benefit for angiotensin- converting-enzyme (ACE) inhibitors for a new set of indications...

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double blind, placebo-controlled, multicentre trial (the EUROPA study)
K. M. Fox; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators

It is well established that angiotensin-converting enzyme (ACE) inhibition effectively reduces mortality and morbidity among patients with heart failure, left ventricular dysfunction, after myocardial infarction (MI), with hypertension, and among other highrisk patients...

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Scandinavian Simvastatin Survival Study Group

Prior to 1994, when this study was published, there had been several trials of cholesterol-lowering interventions in primary and secondary prevention...

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
F. M. Sacks, M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. Arnold, C. C. Wun, et al; Cholesterol and Recurrent Events Trial investigators

CARE (Cholesterol And Recurrent Events) was designed to answer the question of how to treat patients following myocardial infarction (MI), in whom cholesterol levels were within the accepted normal range...

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial
Heart Protection Study Collaborative Group

The correlation between low-density lipoprotein (LDL) cholesterol and ischemic heart disease (IHD) risk had been observed for some years prior to the inception of this trial...

An overview of randomized trials of rehabilitation with exercise after myocardial infarction
G. T. O'Connor, J. E. Buring, S. Yusuf, S. Z. Goldhaber, E. M. Olmstead, R. S. Paffenbarger Jr, C. H. Hennekens

Exercise training has been historically accepted as being of benefit following myocardial infarction (MI). Indeed, Heberden observed in 1772 that one of his patients with presumed ischemic heart disease was “nearly cured” after 6 months of daily wood sawing for half an hour...